Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 7/20 | 0.50 |
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 4/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494201 | 0.91 | CTSS (0.54) | TACR1CTSSCTSKCTSLACE | |
| SCHEMBL15804392 | 0.87 | TACR1 (0.54) | TACR1CTSSCTSKKLK5CTSL | |
| SCHEMBL15807614 | 0.87 | TACR1 (0.54) | TACR1CTSSCTSKKLK5CTSL | |
| SCHEMBL31725814 | 0.87 | TACR1 (0.54) | TACR1CTSSCTSKKLK5CTSL | |
| SCHEMBL15792307 | 0.87 | TACR1 (0.54) | TACR1CTSSCTSKKLK5CTSL | |
| SCHEMBL28127769 | 0.85 | KLK5 (0.52) | TACR1CTSSCTSKKLK5CTSL | |
| SCHEMBL15792088 | 0.84 | TACR1 (0.48) | TACR1CTSSCTSKKLK5CTSL | |
| SCHEMBL15792087 | 0.84 | TACR1 (0.48) | TACR1CTSSCTSKKLK5CTSL | |
| SCHEMBL7065002 | 0.84 | TACR1 (0.48) | TACR1MAPTTP53SCN9A | |
| SCHEMBL15807804 | 0.81 | TACR1 (0.48) | TACR1CTSSCTSKKLK5CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972340-B2 | Selective protein tyrosine phosphatatase inhibitors | ABBOTT LABORATORIES (US) | 2005-12-06 | — | — | US | disclosed |
| WO-2003072537-A2 | SELECTIVE PROTEIN TYROSINE PHOSPHATATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003020688-A1 | SELECTIVE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | disclosed |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBVIE INC. | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | TACR1 2748/4885CTSS 2380/4885CTSK 2543/4885 |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | TACR1 2748/4885CTSS 2380/4885CTSK 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.